Sie sind bereits registriert?
Loggen Sie sich mit Ihrem Universimed-Benutzerkonto ein:
Sie sind noch nicht registriert?
Registrieren Sie sich jetzt kostenlos auf universimed.com und erhalten Sie Zugang zu allen Artikeln, bewerten Sie Inhalte und speichern Sie interessante Beiträge in Ihrem persönlichen Bereich
zum späteren Lesen. Ihre Registrierung ist für alle Unversimed-Portale gültig. (inkl. allgemeineplus.at & med-Diplom.at)
Effective De-Escalation of B-Cell ALL Induction Therapy
The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin (InO) provides high response rates in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). To explore its efficacy and safety in the frontline setting, investigators in Germany conducted an industry-supported prospective, multicenter, phase 2 trial in 45 patients older than 55 years with newly diagnosed Philadelphia chromosome–negative, CD22-expressing precursor-B-cell ALL.
Induction therapy included 2 or 3 cycles of InO plus dexamethasone, followed by age-adapted consolidation (5 cycles), late intensification (1 cycle), and maintenance chemotherapy (up to 2 years). Intrathecal chemotherapy prophylaxis was administered during all treatment phases. Serial measurable residual disease (MRD) testing was performed by flow cytometry (minimum sensitivity, 1 in 104 cells).
The 43 evaluable patients had a median age of 64 (range, 56–80); 3 had central nervous system involvement at diagnosis, and 12 had high-risk cytogenetic alterations. All patients achieved complete remission (CR) or CR with incomplete peripheral blood count recovery; 53% were MRD negative after two InO cycles, 71% after 3 cycles. With a median follow-up of 2.7 years, 1-year event-free survival (EFS; the primary study endpoint) was 88% and 3-year EFS was 55%. Toxicities during InO cycles occurred mostly in cycle 1 and included cytopenias (58%–74%; most grade 3–4), elevated bilirubin (21%, grade 3–4 in 2%), and elevated transaminases (37%, grade 3–4 in 14%). One patient developed hepatic veno-occlusive disease during cycle 2 of InO induction.
Comment
Older adults with Philadelphia chromosome-negative B-ALL have poor outcomes with traditional multiagent chemotherapy regimens due to leukemia resistance and treatment-related toxicities. InO plus dexamethasone induction was highly efficacious and well-tolerated in this study with most patients achieving MRD-negative CR, and warrants exploration in prospective randomized trials. MRD testing by more-sensitive next-generation sequencing will be of interest. As suggested by an editorialist, further de-escalation of post-InO chemotherapy may be possible, and use of the bispecific antibody blinatumomab or other approaches should be considered for patients who do not achieve MRD-negative remission with InO induction.
Citation(s)
Author:
Stelljes M et al.
Title:
Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome–negative B-precursor ALL.
Source:
J Clin Oncol
2024
Jan
20; [e-pub].
(Abstract/FREE Full Text)
Author:
Logan A.
Title:
Innovating simpler and less toxic frontline management for adults with ALL.
Source:
J Clin Oncol
2024
Jan
20; [e-pub].
(Abstract/FREE Full Text)
Empfohlen von
Michael E. Williams, MD, ScM